doi:10.19983/j.issn.2096-8493.20220107

Abstract

CLC Number:

References 35

[1]	Bates M, O’Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis, 2013, 13(1):36-42. doi: 10.1016/S1473-3099(12)70245-1. doi: 10.1016/S1473-3099(12)70245-1 URL
[2]	Swindells S, Ramchandawi R, Gupta A, et al. One Moth of Rifapentine plus Isoniazid to prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi: 10.1056/NEJMoa1806808. doi: 10.1056/NEJMoa1806808 URL
[3]	Nemes E, Geldenhuys H, Rozot V, et al. tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi: 10.1056/NEJMoa1714021. doi: 10.1056/NEJMoa1714021 URL
[4]	Ottenhoff THM. A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2020, 382(16):1576-1577. doi: 10.1056/NEJMc2001364. doi: 10.1056/NEJMc2001364 URL
[5]	Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020, 20(3)e28-e37.doi: 10.1016/S1473-3099(19)30625-5. doi: 10.1016/S1473-3099(19)30625-5
[6]	Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018, 23(4):359-368. doi: 10.1111/resp.13245. doi: 10.1111/resp.13245 URL
[7]	World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization,2019.
[8]	Elhadi M, Khaled A, Msherghi A. Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. Infect Agent Cancer, 2021, 16(1):72. doi: 10.1186/s13027-021-00413-z. doi: 10.1186/s13027-021-00413-z URL
[9]	Lin CH, Lin CJ, Kuo YW, et al. Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis, 2014, 14:5. doi: 10.1186/1471-2334-14-5. doi: 10.1186/1471-2334-14-5 URL
[10]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[11]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X
[12]	Shu CC, Liao KM, Chen YC, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep, 2019, 9(1):11901. doi: 10.1038/s41598-019-48395-8. doi: 10.1038/s41598-019-48395-8 URL
[13]	Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest, 2014, 145(6):1286-1297. doi: 10.1378/chest.13-2137. doi: 10.1378/chest.13-2137 URL
[14]	Hu HY, Wu CY, Huang N, et al. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiol Infect, 2014, 142(1):191-199. doi: 10.1017/S0950268813000551. doi: 10.1017/S0950268813000551 pmid: 23510593
[15]	Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis, 2009, 48(12):1657-1665. doi: 10.1086/599035. doi: 10.1086/599035 pmid: 19445585
[16]	Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One, 2017, 12(3):e0173250. doi: 10.1371/journal.pone.0173250. doi: 10.1371/journal.pone.0173250
[17]	Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol, 2020, 115(3):340-349. doi: 10.14309/ajg.0000000000000527. doi: 10.14309/ajg.0000000000000527 URL
[18]	Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol, 2020, 39(5):1439-1447. doi: 10.1007/s10067-019-04866-x. doi: 10.1007/s10067-019-04866-x URL
[19]	Hosseini M, Shakerimoghaddam A, Ghazalibina M, et al. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries; A systematic review and meta-analysis of cross-sectional studies. Microb Pathog, 2020, 141:104018. doi: 10.1016/j.micpath.2020.104018. doi: 10.1016/j.micpath.2020.104018 URL
[20]	Wong RJ, Hubbard A, Bagley L, et al. Estimating Prevalence of Hepatitis B Virus Coinfection Among Adults With Tuberculosis: A Systematic Review With Meta-analysis. J Clin Gastroenterol, 2022, 56(7):601-617. doi: 10.1097/MCG.0000000000001533. doi: 10.1097/MCG.0000000000001533 URL
[21]	Behzadifar M, Heydarvand S, Behzadifar M, et al. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci, 2019, 29(1):945-956. doi: 10.4314/ejhs.v29i1.17. doi: 10.4314/ejhs.v29i1.17 pmid: 30700963
[22]	姚琳, 顾斌斌, 王霞芳, 等. 苏州地区2011年—2017年间9528例肺结核患者合并症的原因分析及其分布趋势. 抗感染药学, 2019, 16(2):258-261. doi: 10.13493/j.issn.1672-7878.2019.02-025. doi: 10.13493/j.issn.1672-7878.2019.02-025
[23]	邓岚兰, 杨新婷, 贾俊楠, 等. 2012—2016年北京市胸科医院肺结核合并症患者的回顾性分析. 疾病监测, 2018, 33(4):320-323.
[24]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[25]	World Health Organization.World Health Statistics 2019.Geneva:World Health Organization, 2019.
[26]	The World Bank New World Bank country classifications by income level:2020-2021:[EB/OL].[2022-06-11]. https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2020-2021.
[27]	Sbrana E, Grise J, Stout C, et al. Co-morbidities associated with tuberculosis in an autopsy case series. Tuberculosis (Edinb), 2011, 91 Suppl 1:S38-42. doi: 10.1016/j.tube.2011.10.008. doi: 10.1016/j.tube.2011.10.008
[28]	Drug Interactions Checker[DB/OL].[2022-06-12]. https://www.drugs.com/drug_interactions.html.
[29]	Tao NN, Li YF, Song WM, et al. Risk factors for drug-resis-tant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China,during 2004—2019. BMJ Open, 2021, 11(6):e044349. doi: 10.1136/bmjopen-2020-044349. doi: 10.1136/bmjopen-2020-044349
[30]	何燕超, 揭志军. 综合医院活动性肺结核的早期筛查的进展与策略. 结核与肺部疾病杂志, 2022, 4(4):334-337. doi: 10.19983/j.issn.2096-8493.20220078. doi: 10.19983/j.issn.2096-8493.20220078
[31]	周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展. 结核与肺部疾病杂志, 2022, 4(4):338-342. doi: 10.19983/j.issn.2096-8493.20220013. doi: 10.19983/j.issn.2096-8493.20220013
[32]	钱晓文, 翟晓文. 造血干细胞移植与结核病. 结核与肺部疾病杂志, 2022, 4(4):315-319. doi: 10.19983/j.issn.2096-8493.20220092. doi: 10.19983/j.issn.2096-8493.20220092
[33]	张晓林, 李锋. 肺结核致呼吸衰竭研究进展. 结核与肺部疾病杂志, 2022, 4(4):320-324. doi: 10.19983/j.issn.2096-8493.20220014. doi: 10.19983/j.issn.2096-8493.20220014
[34]	郦源, 郭茹茹, 吕良敬. 结缔组织病合并结核病的研究进展. 结核与肺部疾病杂志, 2022, 4(4):309-314. doi: 10.19983/j.issn.2096-8493.20220011. doi: 10.19983/j.issn.2096-8493.20220011
[35]	刘玉坤, 郭智. 慢性髓系白血病与结核病. 结核与肺部疾病杂志, 2022, 4(4):325-327. doi: 10.19983/j.issn.2096-8493.20220108. doi: 10.19983/j.issn.2096-8493.20220108

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yang Shuqi, Li Feng. Advances in PD1/PD-L1 inhibitors in tuberculosis research [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 94-101.
[2]	Zhang Ying, Guo Chunhui. Research progress in the treatment of tuberculous tracheobronchial stenosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 87-93.
[3]	Yan Wenhua, Chen Wenjun. The value of digital health education in the preventive management of caregivers of patients with bacterial positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 73-78.
[4]	Gu Jinhua, Zhang Panpan. Evaluation of the application value of three detection methods for Mycobacterium tuberculosis in a comprehensive hospital [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 68-72.
[5]	Yan Qinghu, Xue Feng, Yu Yong, Qin Yi, Yan Qingmei, Cui Jia. The value of ultrasound-guided microwave ablation in the treatment of localized tuberculous lesions [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 55-60.
[6]	Qi Wei, Zhao Enyi. The epidemic characteristics and the trends of pulmonary tuberculosis in elderly and non-elderly in central urban area, Tianjin from 2006 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 46-54.
[7]	Yang Yan, Dong Wen, Chen Jianjun, Zhang Yu. Epidemiologic characteristics of pulmonary tuberculosis in Zhuxi County, Shiyan City (2014-2023) [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 40-45.
[8]	Zheng Jianli, Wu Yumei, Zhang Shili, Du Zixian, Li Turong, Chen Shisheng, Lin Wenge. Cost-effectiveness analysis of active tuberculosis screening among high-risk populations in Longyan City, Fujian Province [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 35-39.
[9]	Zhao Yongnian, Zhang Lijie, Wang Tongmin. Analysis of the epidemiological characteristics of reported pulmonary tuberculosis in Xinjiang Production and Construction Corps, 2014—2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 30-34.
[10]	Wan Ying, Pang Xuewen, Zhang Fan. Evaluation on effect of health promotion for tuberculosis prevention and control in Tianjin City from 2010 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 22-29.
[11]	Chen Yu, Li Xiaorui, Wang Miaoran, Zhang Yuqi, Liu Chang, Wang Zhaohua, Shi Jie, Fan Lichao, Yin Zhihua, Xie Jianping. The research progress on the role of metal ions in tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 102-112.
[12]	Chen Jing, Qin Yali, Wang Mingdong, Yang Rubin, Wang Qian, Peng Yanqing, Qiu Jiyao, Zhang Xiao, Zhou Xinai. The value of QuantiFERON-TB Gold Plus in the clinical diagnosis of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 61-67.
[13]	Liao Ying, Pang Yan, Zhao Jing, He Gaoqin, You Maolin, Wang Lei. Analysis on the reporting and case finding delay characteristics of pulmonary tuberculosis patients in Liangping District, Chongqing from 2018 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 8-13.
[14]	. [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 495-499.
[15]	Hu Xinyang, Gao Jingtao. Interpretation of WHO global tuberculosis report 2024 [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 500-504.